17 November 2020

Shedding light on viral infections

Bianca-Olivia Nita

In times of a pandemic, there is not a day that goes by without news about viruses. Still, the newest paper from the lab of Oncode Investigator Marvin Tanenbaum, performed in collaboration with the group of Frank van Kuppeveld (University Utrecht), is something special. Based on SunTag technology, they have developed a way to visualize viral infection by plus strand RNA viruses on a single molecule resolution. The technology termed ‘virus infection real-time imaging (VIRIM)’ allows studying the first few hours after a virus infects a cell. These first few hours were difficult to study, as most analytical methods available require more time to pass in order to obtain sufficient signal for analysis. The single molecule approach bypasses this requirement and also allows taking heterogeneity between cells into the equation.

In the manuscript, with PhD student Sanne Boersma as first author, the team uses a specific strain of picorna virus containing multiple SunTags. This system allowed the identification of 5 distinct phases in viral infection. A key step is the replication of viral RNA, this is a bottleneck for viruses to become successful and presents a major target for antiviral therapy. While it may be too late in the game to combat SARS-CoV-2, the tools developed in this study will be of great value to identify vulnerabilities RNA+ viruses. After all, Zika, hepatitis-C and dengue all belong to this class.

Improving cancer treatments?

But there is more. Next to the implications for combating infectious diseases, the technology described above has the possibility to be exploited to study a viral approach to combat cancer. Viruses have the capacity to invade and kill host cells in a rather specific way. For several years, research across the globe has focused on exploiting these features to combat cancer, but it proves to be difficult.

Using oncolytic viruses, tumour cells can be specifically targeted for destruction. There is however a fine line to be walked here, it is a true balancing act. When a virus is so aggressive to kill the tumour cell it infects, there will less time for the infected cell to sense the viral RNA and activate its cellular immune system. This cellular immune response kickstarts the response of specialized immune cells, which are important to combat the primary tumor as well as metastases. When an oncolytic virus is however to slow and benign, it does activate the cellular immune system, but it does not effectively kill the tumour cells anymore. The VIRIM technology creates new avenues to study this process and to get this balance right. The high temporal and spatial resolution can give a boost to finding the optimal window of opportunity for oncolytic viruses.

This study exemplifies the way we look at the power of basic science within Oncode. It all starts with a basic scientific question: how does viral infection and replication works? Based on the answers from this study, we may find new ways to combat both infectious diseases and cancer.

You can read more about this finding and see what it looks like at the NOS (in Dutch).

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
PeterThijssen
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.
Bianca-OliviaNita